

What is claimed is:

1. Crystalline *N*-(3-(5-((1-ethylpiperidin-4-yl)(methyl)amino)-3-(pyrimidin-5-yl)-1*H*-pyrrolo[3,2-*b*]pyridin-1-yl)-2,4-difluorophenyl)propane-1-sulfonamide monosuccinate salt.
2. The crystalline salt of claim 1 which is substantially anhydrous and non-solvated.
3. The crystalline salt of claim 1 or 2 having an X-ray powder diffraction pattern comprising at least one of the following peaks, in terms of 2θ : $15.4^\circ \pm 0.5^\circ$; $20.0^\circ \pm 0.5^\circ$; and $21.8^\circ \pm 0.5^\circ$.
4. The crystalline salt of claim 3, wherein the peak at $15.4^\circ \pm 0.5^\circ$; $20.0^\circ \pm 0.5^\circ$; $21.8^\circ \pm 0.5^\circ$ is the peak of the highest relative intensity in the X-ray powder diffraction pattern.
5. The crystalline salt of any one of claims 1 to 4 having an X-ray powder diffraction pattern comprising at least one of the following peaks, in terms of 2θ : $15.4^\circ \pm 0.2^\circ$; $20.0^\circ \pm 0.2^\circ$; and $21.8^\circ \pm 0.2^\circ$.
6. The crystalline salt of claim 5, wherein the peak at $15.4^\circ \pm 0.2^\circ$; $20.0^\circ \pm 0.2^\circ$; or $21.8^\circ \pm 0.2^\circ$ is the peak of the highest relative intensity in the X-ray powder diffraction pattern.
7. The crystalline salt of any one of claims 1 to 6 having an X-ray powder diffraction pattern comprising at least one peak, in terms of 2θ , at $15.4^\circ \pm 0.5^\circ$.
8. The crystalline salt of claim 7, wherein the peak at $15.4^\circ \pm 0.5^\circ$ is the peak of the highest relative intensity in the X-ray powder diffraction pattern.
9. The crystalline salt of any one of claims 1 to 8 having an X-ray powder diffraction pattern comprising at least one peak, in terms of 2θ , at $15.4^\circ \pm 0.2^\circ$.
10. The crystalline salt of claim 9, wherein the peak at $15.4^\circ \pm 0.2^\circ$ is the peak of the highest relative intensity in the X-ray powder diffraction pattern.
11. The crystalline salt of any one of claims 1 to 10 having an X-ray powder diffraction pattern comprising the following peaks, in terms of 2θ : $15.4^\circ \pm 0.5^\circ$; $20.0^\circ \pm 0.5^\circ$; and $21.8^\circ \pm 0.5^\circ$.

12. The crystalline salt of claim 11, wherein a peak at $15.4^{\circ} \pm 0.5^{\circ}$; $20.0^{\circ} \pm 0.5^{\circ}$; $21.8^{\circ} \pm 0.5^{\circ}$ is the peak of the highest relative intensity in the X-ray powder diffraction pattern.
13. The crystalline salt of any one of claims 1 to 12 having an X-ray powder diffraction pattern comprising the following peaks, in terms of 2θ : $15.4^{\circ} \pm 0.2^{\circ}$; $20.0^{\circ} \pm 0.2^{\circ}$; and $21.8^{\circ} \pm 0.2^{\circ}$.
14. The crystalline salt of claim 13, wherein a peak at $15.4^{\circ} \pm 0.2^{\circ}$; $20.0^{\circ} \pm 0.2^{\circ}$; or $21.8^{\circ} \pm 0.2^{\circ}$ is the peak of the highest relative intensity in the X-ray powder diffraction pattern.
15. The crystalline salt of claim 1 having an X-ray powder diffraction pattern substantially as shown in FIG. 10, FIG. 26, or FIG. 38; or a differential scanning calorimetry thermogram (DSC) substantially as shown in FIG. 11, FIG. 27, or FIG. 39; or a thermogravimetric analysis (TGA) substantially as shown in FIG. 12, FIG. 28 or FIG. 39.
16. A composition comprising the crystalline salt of any one of claims 1 to 15.
17. A process for preparing the crystalline salt of any one of claims 1 to 15 comprising reacting *N*-(3-(5-((1-ethylpiperidin-4-yl)(methyl)amino)-3-(pyrimidin-5-yl)-1*H*-pyrrolo[3,2-*b*]pyridin-1-yl)-2,4-difluorophenyl)propane-1-sulfonamide with one equivalent of succinic acid.
18. The process of claim 17 further comprising crystallizing the salt from a C₁₋₄ alcohol or aqueous C₁₋₄ alcohol or ethyl acetate.
19. Use of a therapeutically effective amount of a crystalline salt of any one of claims 1 to 15 in the manufacture of a medicament for the treatment of a disease associated with abnormal expression or activity of a RAF kinase in a patient in need thereof.
20. Use of a therapeutically effective amount of a crystalline salt of any one of claims 1 to 15 in the manufacture of a medicament for the treatment of cancer in a patient in need thereof.